498
The development of an IgG lambda-type monoclonal gammopathy and subsequent multiple myeloma in an epilepsy patient on diphenylhydantoin (DILANTIN) therapy for 20 years is reported.
 an epilepsy patient: Subject; an IgG lambda-type monoclonal gammopathy and subsequent multiple myeloma: Effect; diphenylhydantoin (DILANTIN) therapy for 20 years: Treatment; epilepsy: Treatment.Disorder; diphenylhydantoin: Treatment.Drug; for 20 years: Treatment.Duration
Given event type and trigger, please tell me the arguments of all the listed option. Output format is "name1: role1; name2: role2". 
Event type: adverse event 
  Option: Treatment.Freq, Subject.Population, Combination.Drug, Subject.Gender, Treatment.Duration, Subject, Effect, Treatment, Treatment.Disorder, Subject.Disorder, Treatment.Route, Subject.Race, Treatment.Time_elapsed, Treatment.Dosage, Subject.Age, Treatment.Drug 
Text: {0} 
Answer:
 an epilepsy patient: Subject; an IgG lambda-type monoclonal gammopathy and subsequent multiple myeloma: Effect; diphenylhydantoin (DILANTIN) therapy for 20 years: Treatment; epilepsy: Treatment.Disorder; diphenylhydantoin: Treatment.Drug; for 20 years: Treatment.Duration